ES2733767T3 - Método para la fabricación de derivados de hidroxietilalmidón - Google Patents

Método para la fabricación de derivados de hidroxietilalmidón Download PDF

Info

Publication number
ES2733767T3
ES2733767T3 ES12737229T ES12737229T ES2733767T3 ES 2733767 T3 ES2733767 T3 ES 2733767T3 ES 12737229 T ES12737229 T ES 12737229T ES 12737229 T ES12737229 T ES 12737229T ES 2733767 T3 ES2733767 T3 ES 2733767T3
Authority
ES
Spain
Prior art keywords
value
temperature
solution
iron
hydroxyethyl starch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12737229T
Other languages
English (en)
Spanish (es)
Inventor
Werner Zimmermann
Jan Lukowczyk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SERUMWERK BERNBURG AG
Original Assignee
SERUMWERK BERNBURG AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44799422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2733767(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SERUMWERK BERNBURG AG filed Critical SERUMWERK BERNBURG AG
Application granted granted Critical
Publication of ES2733767T3 publication Critical patent/ES2733767T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00Preparation of derivatives of starch
    • C08B31/08Ethers
    • C08B31/12Ethers having alkyl or cycloalkyl radicals substituted by heteroatoms, e.g. hydroxyalkyl or carboxyalkyl starch
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/26Iron; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00Preparation of derivatives of starch
    • C08B31/08Ethers
    • C08B31/10Alkyl or cycloalkyl ethers
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00Preparation of derivatives of starch
    • C08B31/18Oxidised starch
    • C08B31/185Derivatives of oxidised starch, e.g. crosslinked oxidised starch

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES12737229T 2011-06-21 2012-06-21 Método para la fabricación de derivados de hidroxietilalmidón Active ES2733767T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11170761A EP2537866A1 (en) 2011-06-21 2011-06-21 Hydroxyethyl starch derivatives, method for manufacturing the same and therapeutical uses thereof
PCT/EP2012/061958 WO2012175608A1 (en) 2011-06-21 2012-06-21 Method for manufacturing hydroxyethyl starch derivatives

Publications (1)

Publication Number Publication Date
ES2733767T3 true ES2733767T3 (es) 2019-12-02

Family

ID=44799422

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12737229T Active ES2733767T3 (es) 2011-06-21 2012-06-21 Método para la fabricación de derivados de hidroxietilalmidón

Country Status (22)

Country Link
US (2) US9181353B2 (cg-RX-API-DMAC7.html)
EP (2) EP2537866A1 (cg-RX-API-DMAC7.html)
JP (2) JP6370217B2 (cg-RX-API-DMAC7.html)
CN (2) CN103649128B (cg-RX-API-DMAC7.html)
BR (1) BR112013032901A2 (cg-RX-API-DMAC7.html)
CA (1) CA2837784C (cg-RX-API-DMAC7.html)
CY (1) CY1121976T1 (cg-RX-API-DMAC7.html)
DK (1) DK2723774T3 (cg-RX-API-DMAC7.html)
ES (1) ES2733767T3 (cg-RX-API-DMAC7.html)
HK (1) HK1220218A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20191173T1 (cg-RX-API-DMAC7.html)
HU (1) HUE044428T2 (cg-RX-API-DMAC7.html)
LT (1) LT2723774T (cg-RX-API-DMAC7.html)
MX (1) MX337682B (cg-RX-API-DMAC7.html)
PL (1) PL2723774T3 (cg-RX-API-DMAC7.html)
PT (1) PT2723774T (cg-RX-API-DMAC7.html)
RS (1) RS59021B1 (cg-RX-API-DMAC7.html)
SI (1) SI2723774T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900430T1 (cg-RX-API-DMAC7.html)
TR (1) TR201909574T4 (cg-RX-API-DMAC7.html)
TW (1) TWI564010B (cg-RX-API-DMAC7.html)
WO (1) WO2012175608A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6616725B2 (ja) * 2016-03-31 2019-12-04 日本製紙株式会社 塗工紙用澱粉
WO2020144667A1 (en) 2019-01-10 2020-07-16 Pharmacosmos Holding A/S Treating iron deficiency in subjects at risk of cardiovascular adverse events and iron for the management of atrial fibrillation
CN114286682A (zh) 2019-02-09 2022-04-05 法码科思莫斯控股有限公司 治疗具有心血管不良事件风险的个体的铁缺乏以及用于治疗心房颤动的铁
KR20240041957A (ko) 2021-08-03 2024-04-01 파르마코스모스 홀딩 에이/에스 반려동물의 철 결핍증 치료방법에서 피하 사용을 위한 철 착화합물
CN117547549A (zh) * 2023-11-09 2024-02-13 黑龙江八一农垦大学 适用于犬arf的腹膜透析液与助清除剂的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639588A (en) * 1966-10-22 1972-02-01 Fisons Pharmaceuticals Ltd Pharmaceutical compositions containing ferric hydroxide complexed with dextran or dextrin heptonic acids
US4370476A (en) * 1979-07-17 1983-01-25 Usher Thomas C Dextran polycarboxylic acids, ferric hydroxide complexes
GB8902894D0 (en) * 1989-02-09 1989-03-30 Fisons Plc Compositions
JPH0566372A (ja) * 1991-09-10 1993-03-19 Fukui Megane Kogyo Kk 金属製眼鏡フレーム部品の製造方法
JPH0776524A (ja) * 1993-07-13 1995-03-20 Takeda Chem Ind Ltd 動物用抗貧血剤
DK172860B1 (da) * 1998-03-25 1999-08-16 Pharmacosmos Holding As Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman
DK173138B1 (da) * 1998-11-20 2000-02-07 Pharmacosmos Holding As Fremgangsmåde til fremstilling af en jerndextranforbindelse, jerndextranforbindelse fremstillet efter fremgangsmåden, farma
EP1762250A1 (en) * 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
EP2176215B1 (en) * 2007-08-17 2014-10-08 Akzo Nobel N.V. Glutamic acid n,n-diacetic amide, glutamic acid n-acetic amide n-acetonitrile, alkali metal salts thereof, process to prepare them and their use
TWI469965B (zh) * 2008-12-22 2015-01-21 Ono Pharmaceutical Co 乙炔基吲哚化合物
JP5397991B2 (ja) * 2009-04-01 2014-01-22 学校法人東京農業大学 乳酸菌を用いたビタミンb12の定量方法

Also Published As

Publication number Publication date
MX2013015075A (es) 2014-04-14
US20160046733A1 (en) 2016-02-18
MX337682B (es) 2016-03-15
RS59021B1 (sr) 2019-08-30
HK1220218A1 (zh) 2017-04-28
CA2837784C (en) 2019-10-15
WO2012175608A1 (en) 2012-12-27
PL2723774T3 (pl) 2019-10-31
DK2723774T3 (da) 2019-07-15
CA2837784A1 (en) 2012-12-27
TWI564010B (zh) 2017-01-01
JP2014520188A (ja) 2014-08-21
BR112013032901A2 (pt) 2017-01-24
US9181353B2 (en) 2015-11-10
HRP20191173T1 (hr) 2019-10-04
TR201909574T4 (en) 2019-08-21
EP2723774A1 (en) 2014-04-30
SI2723774T1 (sl) 2019-08-30
SMT201900430T1 (it) 2019-09-09
HUE044428T2 (hu) 2019-10-28
EP2723774B1 (en) 2019-04-03
CY1121976T1 (el) 2020-10-14
US9631032B2 (en) 2017-04-25
EP2537866A1 (en) 2012-12-26
CN103649128A (zh) 2014-03-19
CN105348401A (zh) 2016-02-24
JP6370217B2 (ja) 2018-08-08
TW201315474A (zh) 2013-04-16
PT2723774T (pt) 2019-07-15
CN103649128B (zh) 2016-02-10
JP2018100424A (ja) 2018-06-28
LT2723774T (lt) 2019-08-12
US20140128594A1 (en) 2014-05-08

Similar Documents

Publication Publication Date Title
ES2733767T3 (es) Método para la fabricación de derivados de hidroxietilalmidón
Pelegrino et al. Photochemistry of nitric oxide and S-nitrosothiols in human skin
Pan et al. Enzyme-mimic catalytic activities and biomedical applications of noble metal nanoclusters
Lv et al. Indocyanine green-equipped upconversion nanoparticles/CeO2 trigger mutually reinforced dual photodynamic therapy
CN107201387A (zh) 一种右旋糖酐铁的制备方法
ES2777838T3 (es) Cristal de anhidrato de N-acetilneuraminato de amonio y procedimiento para producir el mismo
RS59704B1 (sr) Antitela protiv hpa-1a
Sarkar et al. Review of prodrug and nanodelivery strategies to improve the treatment of colorectal cancer with fluoropyrimidine drugs
Li et al. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results
CN102227222B (zh) 抗肿瘤药物,生产该药物的方法和稳定该药物的方法
CN104387501A (zh) 壳聚糖定位酰化缩氨基硫脲类衍生物及其制备方法
CN110237028A (zh) 一种硫辛酸注射液及制备工艺
JP6757016B2 (ja) 多硫酸化プロテオグリカン
CN105949344B (zh) 一种阳离子超支化多糖衍生物及其在增强血卟啉类光敏剂对肿瘤细胞光毒性方面的应用
van Ballegooie et al. Gold–protein composite nanoparticles for enhanced X-ray interactions: a potential formulation for triggered release
Wu et al. A Cyclodextrin Odyssey in the Stoddart Group: From Syntheses to Applications
CN106519071A (zh) 一种抗肿瘤药物6‑羟基亚硒酸酯化壳聚糖铜的合成方法
TW200538457A (en) Aqueous solutions comprising camptothecin
JP6786064B2 (ja) 上皮細胞増殖剤
Bhaskar et al. Leveraging the potential of carbon: carbon quantum dots as a versatile probe for cancer diagnosis and treatment.
CN103613626B (zh) 一种环磷腺苷化合物及其环磷腺苷葡胺药物组合物
ES2434040T3 (es) Procedimiento para producir un agente anticanceroso
Ma et al. Recent Advances in Supramolecular Systems for Precision Medicine: Structural Design, Functional Integration, and Clinical Translation Challenges
WO2022146323A1 (en) A novel platinum-based organometallic compound for the treatment of lung cancer and the synthesis method of the compound
CN111529507A (zh) 新型顺铂纳米的生物降解新型医药组合物及制备方法